Is Librela Safe for Dogs? FDA Alert & Side Effects

Librela (bedinvetmab) has a favorable safety profile in controlled clinical trials lasting two to three months, but post-market reports of serious adverse events, including deaths, prompted the FDA’s Center for Veterinary Medicine to issue safety communications urging closer monitoring. The drug is not considered dangerous for most dogs with osteoarthritis pain, yet the gap between short-term trial data and the growing volume of real-world adverse event reports has made veterinarians and dog owners understandably cautious. The picture is more complicated than either “perfectly safe” or “too risky,” and the details matter.

What Librela Is and How It Works

Librela is a monoclonal antibody designed specifically for dogs. Its active ingredient, bedinvetmab, targets a protein called nerve growth factor (NGF). In adult animals, NGF plays a central role in how pain signals travel and intensify, particularly in chronic conditions like osteoarthritis. By binding to NGF before it can activate pain-signaling receptors, bedinvetmab essentially intercepts pain at the source rather than masking it the way traditional painkillers do.¹ The drug is given as a once-monthly injection at your veterinarian’s office, which removes the daily-pill compliance problem that plagues many dog owners.

Because bedinvetmab is “caninized,” meaning it was engineered to look like a naturally occurring dog antibody, the immune system is less likely to flag it as foreign. In a laboratory safety evaluation, researchers found no treatment-emergent immunogenicity, meaning the dogs’ immune systems did not generate antibodies against the drug itself during the study period.² That is a reassuring finding for a drug meant to be used long-term, though it does not eliminate the possibility of immune reactions in a broader, more diverse population of dogs.

What the FDA Flagged

The FDA’s Center for Veterinary Medicine has issued safety communications about Librela based on adverse event reports submitted after the drug reached the market. These reports include a range of problems: musculoskeletal issues, neurological signs, injection-site reactions, and, in some cases, death. It is worth understanding what an FDA adverse event report actually represents. These reports are filed by veterinarians and pet owners, and they describe events that occurred after a dog received the drug. They do not, on their own, prove the drug caused those events. A dog with advanced osteoarthritis already has joint deterioration in progress, and distinguishing drug-related worsening from natural disease progression is genuinely difficult.

That said, the volume of reports attracted enough attention for the FDA to publicly flag the issue, which is not something the agency does lightly for veterinary products. The agency has not withdrawn Librela from the market or issued a recall. Instead, the communications emphasize that veterinarians and owners should weigh the benefits of pain control against possible risks, report any suspected adverse events, and monitor dogs closely after each injection.

What Controlled Clinical Trials Actually Found

The clinical trial picture looks quite different from the post-market reports, in part because trials are shorter and more controlled. In a prospective, randomized, placebo-controlled study evaluating bedinvetmab for osteoarthritis pain, adverse events were similar between the treatment group and the placebo group and were not considered treatment-related.³ A second placebo-controlled field study in the United States found essentially the same thing: adverse event rates did not differ meaningfully between dogs getting the drug and dogs getting a placebo injection.⁴

A critical appraisal that reviewed the available safety literature confirmed this pattern: two studies covering three-month treatment periods found no increase in adverse events compared to placebo. A third study comparing bedinvetmab to meloxicam over two months found fewer adverse events in the bedinvetmab group. However, the same appraisal noted that a disproportionality analysis of pharmacovigilance data found musculoskeletal adverse events reported significantly more frequently in bedinvetmab-treated dogs than in dogs on other traditional pain therapies.⁵ That discrepancy between trial data and real-world reporting is at the heart of the current debate.

The Rapidly Progressive Joint Disease Question

Among the more alarming adverse events linked to anti-NGF therapy, in both human and veterinary medicine, is a condition called rapidly progressive osteoarthritis, sometimes abbreviated RPOA. In RPOA, a joint deteriorates much faster than expected, with bone loss and structural collapse happening over weeks to months rather than years. Researchers have flagged emerging signs of rapidly progressive arthritic changes in dogs and cats receiving bedinvetmab and its feline counterpart, frunevetmab.⁶

The theoretical concern is straightforward. NGF does more than transmit pain. It appears to play a role in how joints maintain and repair themselves. Block NGF effectively enough, and a dog may feel well enough to use a damaged joint more vigorously while the biological signals needed for tissue maintenance are simultaneously dulled. Whether this is what is actually happening in reported RPOA cases, or whether these dogs simply had joints that were already on the verge of collapse, remains an open question. A recent review specifically examined whether RPOA in Librela-treated dogs represents an expected consequence of the drug’s mechanism or a distinct safety concern warranting caution.⁷

For owners, the practical takeaway is that a dog on Librela should not be treated as if its joints have healed. The pain relief can be dramatic enough that a previously limping dog starts running and jumping again, and that increased activity on a structurally compromised joint could accelerate damage. Controlled exercise and ongoing veterinary monitoring of joint health, ideally with periodic imaging, are sensible precautions.

How Librela Compares to NSAIDs

For years, nonsteroidal anti-inflammatory drugs like meloxicam, carprofen, and grapiprant were the mainstays of canine osteoarthritis pain management. They work, but they carry well-known risks: gastrointestinal ulceration, kidney stress, and liver toxicity, particularly with long-term use. Dogs that cannot tolerate NSAIDs, or that have pre-existing kidney or liver problems, often had few good options before Librela came along.

A head-to-head trial comparing bedinvetmab to meloxicam found that both drugs were equally effective at controlling osteoarthritis pain, but the bedinvetmab group reported only four adverse events while the meloxicam group reported 17, nine of which were gastrointestinal disorders. More dogs in the bedinvetmab group completed the study as well.⁸ In a separate study using force-plate gait analysis, an objective measure of how much weight a dog places on a limb, bedinvetmab was found to be non-inferior to grapiprant. Roughly 69% of dogs in the bedinvetmab group showed measurable improvement at six weeks compared to about 56% in the grapiprant group, and the statistical analysis confirmed non-inferiority.⁹

These comparisons paint Librela in a favorable light, particularly on the gastrointestinal front. But they also highlight an important nuance: the advantage of Librela is not that it is more effective than NSAIDs. It is roughly equivalent. Its advantage lies in a different side-effect profile, one that trades GI and organ toxicity risks for the still-being-understood musculoskeletal and neurological concerns flagged in post-market surveillance. Whether that trade-off works for your dog depends on your dog’s specific health situation.

Why Your Perception of Improvement May Not Be Reliable

One complicating factor in evaluating any osteoarthritis treatment is the caregiver placebo effect. A well-known study found that when dogs with osteoarthritis-related lameness received a placebo injection, their owners reported improvement about 40% of the time. Objective measurements of the dogs’ gait, using ground reaction forces, showed no actual change.¹⁰ Veterinarians were also susceptible, though the study emphasized that owners were particularly prone to seeing improvement that was not there.

This does not mean Librela does not work. The force-plate studies cited above use objective measurements that are not influenced by owner expectations, and they show real improvements in limb loading. But it does mean that if you start Librela and your dog seems better within a day or two, before the drug has had time to reach full effect, some of that perceived improvement may be hope rather than pharmacology. Conversely, if your dog seems unchanged after the first injection but objective measures would show improvement, you might prematurely conclude the drug failed. Discuss with your vet how to evaluate response over time rather than relying solely on your own impression.

What “No Antidote” Means in Practice

Unlike an NSAID that clears the body within a day or two if you stop giving it, a monoclonal antibody like bedinvetmab has a long half-life. Once injected, it circulates for weeks. If your dog has a serious adverse reaction, there is no way to pull the drug out of the system. You simply have to wait for the body to clear it naturally. This is one of the more important practical differences between Librela and traditional painkillers, and it is something the FDA communications have highlighted.

For most dogs, this long duration is actually the selling point: one injection lasts a month, no daily pills, no missed doses. But for a dog experiencing a bad reaction, those same weeks feel very different. The inability to reverse the drug quickly means that the decision to start Librela should be made with some care. Many veterinarians recommend starting with a single injection and monitoring closely for a full month before committing to ongoing treatment. If a dog tolerates the first dose well, the risk of serious problems with subsequent doses appears to be lower, though it is not zero.

Dogs That May Need Extra Caution

The product label and veterinary guidance generally advise against using Librela in dogs under 12 months old, since NGF plays important roles in the developing nervous system. Breeding dogs and pregnant or lactating dogs are also typically excluded, as the effects of NGF blockade on reproduction and fetal development have not been adequately studied.

Dogs with neurological conditions deserve special consideration. Because NGF is involved in nerve maintenance and repair, blocking it in a dog with an existing neuropathy or spinal condition could theoretically worsen nerve function. Some of the post-market neurological reports, including ataxia and other coordination problems, have raised questions about whether certain dogs are more vulnerable. There is no definitive answer yet, but if your dog already has nerve-related symptoms, a frank conversation with your vet about risk versus benefit is warranted.

Dogs with very advanced osteoarthritis, where joints are severely degraded, may be at higher risk for the rapidly progressive joint changes discussed earlier. The more damaged the joint is to begin with, the less structural reserve it has, and the less margin there is if the drug’s pain relief leads to overuse. For these dogs, pain management is still important for quality of life, but the management plan may need to include strict activity modification alongside the medication.

The Renal Question From the Cat Drug

Owners researching anti-NGF therapy sometimes encounter alarming reports about kidney problems. Most of these stem from data on frunevetmab, the feline version of the drug (marketed as Solensia for cats), not from bedinvetmab in dogs. A pharmacovigilance analysis of the FDA’s adverse event database found that frunevetmab had a significant signal for renal and urinary disorders in cats, with both the number of reports and the statistical strength of the signal exceeding background levels.¹¹ This is worth knowing because it suggests that the anti-NGF mechanism itself could have organ-level effects, but cat and dog physiology differ, and the renal signal has not been replicated with the same strength in canine data. Conflating the two products’ safety profiles is a common mistake in online discussions.

Combining Librela With Other Pain Medications

Some veterinarians use Librela alongside other pain medications, particularly for dogs with severe osteoarthritis that does not respond adequately to a single agent. The combination of an anti-NGF antibody with an NSAID, gabapentin, or other analgesics is not uncommon in clinical practice, but it introduces additional unknowns. In human medicine, anti-NGF drugs combined with NSAIDs were associated with higher rates of rapidly progressive joint disease, which is one reason several human anti-NGF programs were slowed or halted by regulators years ago.

Whether the same interaction applies in dogs is not firmly established, but the biological logic is plausible. If NGF blockade reduces the joint’s ability to signal that it needs repair, and an NSAID simultaneously reduces inflammation-driven protective responses, the combined effect on joint integrity could be worse than either drug alone. If your vet recommends combination therapy, ask specifically about this concern and whether periodic joint imaging might be appropriate to catch early signs of accelerated deterioration.

How Long the Safety Data Actually Covers

One point that often gets lost in the debate is how short the controlled safety data really are. The clinical trials evaluating bedinvetmab’s safety covered treatment periods of two to three months.⁵ Osteoarthritis is a lifelong condition, and many dogs will receive Librela monthly for years. The post-market adverse event signals, particularly the musculoskeletal ones, may reflect what happens when NGF blockade is sustained over much longer periods than any trial tested. This is not unusual for veterinary drugs; regulatory approval is often based on relatively short pivotal trials, and the longer-term safety picture fills in gradually through real-world use and pharmacovigilance reporting. But it does mean that anyone starting their dog on Librela today is, in a sense, part of the ongoing safety evaluation. Regular veterinary check-ups and honest reporting of any changes in your dog’s condition contribute to the collective understanding of how this drug performs over time.